Key Leaders' Opinion on Radiotherapy with Immuno-Targeted Therapies
|Editors:||Jiade J. Lu, Lvhua Wang, Bengt Glimelius|
Publisher: AME Publishing Company; 1st edition (2018)
Hardcover: 183 pages
All the while, surgery, radiotherapy and chemotherapy are three major means for cancer therapy. Latest data has indicated that the cure rates for cancer by surgery, radiotherapy and chemotherapy are 49%, 40% and 11% respectively. With the extensive clinical application of a variety of image-guidance technology, intensity modulation technique and radiotherapy technology such as SBRT, the accuracy of radiotherapy is scaling new heights. In order to achieve better radiotherapeutic effects, the single dose of radiotherapy and biologically equivalent doses have also been gradually enhanced. In this context, the book “Radiotherapy with Immuno-Targeted Therapies” emerged. The book invited a number of internationally well-known experts to summarize the latest advances in the whole or certain aspect of radiotherapy and immunotherapy, or to share their unique insights based on recent clinical research published by world renowned journals. The main authors of this book are from famous universities or cancer centers of the world including the United States, England, France, Germany, Japan, Singapore and so on. This book was co-published simultaneously across the world by AME Publishing Company and Central South University Press in both Chinese and English versions. The goal of this book was to enable readers to systematically and comprehensively understand the latest research results of radiotherapy and immunotherapy.
|Joe Y. Chang||Professor of Radiation Oncology, Director of Stereotactic Ablative Radiotherapy, The University of Texas MD Anderson Cancer Center, Houston, USA|
|Athanassios Argiris||Department of Medical Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, USA; Consultant Medical Oncologist, Hygeia Hospital, Athens, Greece|
|Jiade J. Lu||Shanghai Proton and Heavy Ion Center, Shanghai, China|
|Lvhua Wang||Department of Radiotherapy, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China|
|Bengt Glimelius||Department of Immunology, Genetics and Pathology, Uppsala University/University Hospital, SE-751 85 Uppsala, Sweden|
|Haval Shirwan||Department of Microbiology and Immunology, Institute for Cellular Therapeutics, University of Louisville, Louisville, KY 402002, USA|
|Yongzhong Wu||Department of Radiotherapy, Chongqing Cancer Hospital, Chongqing, China|
|Shenglin Ma||Department of Radiation Oncology, Hangzhou First People's Hospital, Zhejiang Province, China|
|Hongcheng Zhu||Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China|
|Mingwei Ma||Department of Radiation Oncology, Peking University First Hospital, Beijing, China|
|Jiayan Chen||Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China|
Table of Contents
1 Immunological interactions in radiotherapy—opening a new window of opportunity
9 Chemically enhanced radiotherapy: visions for the future
Basic and Preclinial Investigation
17 Irradiation and combination immunotherapy
21 Radiotherapy: killing with complement
26 Complementing the tumor-specific immunity in tumor radiotherapy
28 Fractionated radiotherapy combined with PD-1 pathway blockade promotes CD8 T cell-mediated tumor clearance for the treatment of advanced malignancies
32 Optimizing radiation for cancer immunotherapy
35 CD8+ T effector targeted elimination of regulatory tumor stroma cells for improved immunotherapy
37 Expanding landscape of CDKN1A (p21) functions: CDKN1A-mediated radioresistance of dermal Langerhans cells and its impact on the immune system
40 STING-cytosolic DNA sensing: the backbone for an effective tumor radiation therapy
43 Combination therapy with TLR7 agonist and radiation is effective for the treatment of solid cancer
46 Integr(at)in(g) EGFR therapy in HNSCC
Translational Research and Clinical Trials
50 Radiation therapy and the abscopal effect: a concept comes of age
53 Immunologic response of combined interleukin-2 and stereotactic body radiotherapy
58 Radiation, cytokines and T-cell checkpoints: can we cure metastatic cancer?
60 Identification of the hidden survival advantage for anti-angiogenic therapy in glioblastoma
63 Value of correlative biomarkers in understanding tumor biology
65 Sense and sensibility to early combine bevacizumab to radiation treatment of brain metastasis: reply to Lou and Sperduto
67 Integrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach?
72 Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies
80 Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma
90 Cranial irradiation in patients with EGFR-mutant non-small cell lung cancer brain metastases
94 Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?
99 Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?
107 Immunotherapy for nasopharyngeal cancer—a review
117 Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation?
123 Non-surgical treatment for locally advanced head and neck squamous cell carcinoma: beyond the upper limit
128 Anti-epidermal growth factor receptor immunotherapy in combination with cisplatin chemoradiation for patients with advanced head and neck carcinoma—biological and clinical limitations of the triple treatment
132 Postoperative treatment for head and neck cancer: the emerging role of EGFR-targeted therapy